SMURF-Therapeutics, Inc. https://validator.w3.org/feed/docs/rss2.html News archives Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance. SMURF-2 data in 2023 AACR Poster Presentation News-media Resources Header Simple Fullwidth (Education) FOR-INVESTORS Technology Scientific Advisory Board Management SMURF-Therapeutics, Inc. Announces Six New Appointments to Scientific Advisory Board Dr. Emile Youssef appointed Chief Medical Officer at SMURF-Therapeutics, Inc. Pipeline Contact Us Expertise Comming soon Dr. Wafik El-Deiry comments on the future of cancer treatment Smurf2 Regulation of HIF-1α in Cancer Cells SMURF2 predisposes cancer cell toward ferroptosis in GPX4-independent manners by promoting GSTP1 degradation: Molecular Cell Footer Default (Education) FDA approves belzutifan for cancers associated with von Hippel-Lindau disease | FDA Identification of Smurf2 as a HIF-1α degrading E3 ubiquitin ligase | Oncotarget Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease | NEJM SMURF2 predisposes cancer cell toward ferroptosis in GPX4-independent manners by promoting GSTP1 degradation: Molecular Cell The appointment of leadership announcement. Header Main (Education) MailChimp Popup Events Header (Education) Video popup top-header Elementor Landing Page #332 Home